Holen Sie sich die Stockscreener-App
426.00
0.10%
0.43
Handel nachbörslich:
410.00
-16.00
-3.76%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$425.57
Offen:
$428.48
24-Stunden-Volumen:
1.92M
Relative Volume:
1.06
Marktkapitalisierung:
$109.22B
Einnahmen:
$11.39B
Nettoeinkommen (Verlust:
$3.64B
KGV:
30.45
EPS:
13.9904
Netto-Cashflow:
$3.50B
1W Leistung:
+1.39%
1M Leistung:
+5.63%
6M Leistung:
-15.00%
1J Leistung:
-9.58%
1-Tages-Spanne:
$418.60
$430.10
1-Wochen-Bereich:
$415.00
$430.10
52-Wochen-Spanne:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Vertex Pharmaceuticals (VRTX) Reports Strong Q3 2025 Earnings with 11% Revenue Growth - GuruFocus
Vertex Pharmaceuticals Reports Strong Q3 2025 Results - TipRanks
Vertex Reports Third Quarter 2025 Financial Results - BioSpace
Vertex Pharmaceuticals Outpaces Expectations With Fresh Growth - Finimize
Vertex’s cystic fibrosis sales beat expectations, as newer drugs miss - The Boston Globe
Vertex Pharmaceuticals (VRTX) Beats Q3 Expectations, Shares Fall - GuruFocus
Earnings call transcript: Vertex Q3 2025 beats forecasts, stock gains - Investing.com
Why Vertex Skidded Despite Its Beat-And-Raise Quarter - Investor's Business Daily
Vertex falls despite Q3 double beats as 2025 revenue guidance narrowed - Seeking Alpha
Vertex’s Cystic Fibrosis Sales Beat, as Newer Drugs Miss - Bloomberg.com
Vertex Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Vertex Pharmaceuticals (VRTX) Q3 Earnings Surpass Expectations - GuruFocus
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Vertex Pharmaceuticals Grows Past Cystic Fibrosis With New Hits - Finimize
Vertex beats quarterly estimates on cystic fibrosis demand, new drugs - MSN
Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs - MarketScreener
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations - Yahoo Finance
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book - MSN
After pain setback, Vertex spotlights renal portfolio in expectation-beating Q3 - FirstWord Pharma
Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q3 Adjusted EPS $4.80 per Share, vs. FactSet Est of $4.58 - MarketScreener
Earnings Flash (VRTX) Vertex Pharmaceuticals Posts Q3 Adjusted EPS $4.80, vs. FactSet Est of $4.58 - MarketScreener
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Vertex Pharma’s Stock Has Tumbled. Earnings Will Stop the Pain. - MSN
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceWeekly Trade Report & Smart Investment Allocation Tips - newser.com
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsJuly 2025 Macro Moves & Verified Entry Point Signals - newser.com
Published on: 2025-11-03 07:39:53 - newser.com
Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryPortfolio Update Report & Safe Capital Investment Plans - newser.com
Will Vertex Pharmaceuticals Incorporated benefit from macro trends2025 Analyst Calls & Growth Focused Entry Reports - newser.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Tredje AP fonden - MarketBeat
Telos Capital Management Inc. Increases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Torray Investment Partners LLC Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Welch & Forbes LLC - MarketBeat
South Dakota Investment Council Sells 10,780 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-11-03 04:36:10 - newser.com
Mission Wealth Management LP Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated’s volatility index tracking explainedEarnings Performance Report & Free AI Powered Buy and Sell Recommendations - newser.com
Exit strategy if you’re trapped in Vertex Pharmaceuticals IncorporatedMarket Activity Summary & Technical Pattern Based Buy Signals - newser.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Arkadios Wealth Advisors - MarketBeat
Vertex Pharmaceuticals (VRTX): Exploring Valuation After Promising Kidney Therapy Results and Growth in New Treatments - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Holdings Reduced by China Universal Asset Management Co. Ltd. - MarketBeat
Syverson Strege & Co Makes New $283,000 Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Keybank National Association OH Sells 1,523 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-11-02 03:14:13 - newser.com
Momentum divergence signals in Vertex Pharmaceuticals Incorporated chartTrade Volume Report & Capital Protection Trade Alerts - newser.com
Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Vertex Pharmaceuticals Incorporated (VRTX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
VERTEX PHARMACEUTICALS Earnings Preview: Recent $VRTX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Top Biotech Stocks To Keep An Eye OnOctober 28th - MarketBeat
Fisher Funds Management LTD Has $5.74 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Lockheed Martin Investment Management Co. Purchases 2,760 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.47%
0.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):